Use of cholinesterase inhibitors for treatment of Alzheimer disease

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 7, 2001, Pages 608-616

  Hake, Ann Marie ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; SABELUZOLE; TACRINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; ESTROGEN THERAPY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MUSCLE CRAMP; WEIGHT REDUCTION;

EID: 0034930446     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.7.608     Document Type: Article

References (15)

1. Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimer's disease Am J Psychiatry 1984; 141:1356-1364.
2. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's djsease. The Tacrine Study Group. JAMA 1994, 271:985-991.
3. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology 1996, 47:166-177.
4. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145
5. Waldemar G, Winblad B, Engedal K, et al. Donepezil benefits patients with either mild or moderate Alzheimer's disease over one year. Neurology 2000; 54(suppl 3):A470.
6. Rosier M, Anand R, Cicin-Sairt A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318:633-638.
7. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD Neurology 2000; 54:2269-2276.
8. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48:1517-1521.
9. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348:429-432.
10. Waring SC, Rocca WA, Peterson RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999; 52.965-970.
11. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000, 283:1007-1015.
12. Hendereon VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blinded, placebo-controlled trial Neurology 2000; 54:295-301.
13. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48:626-632
14. Sano M, Ernesto C, Thomas R, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer disease. N Engl J Med 1997; 336-1216-1222.
15. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 1999; 400:173-177.